natgillin/translations-raw huggingface dataset:
UAB “Sicor Biotech” filiale Latvija Tel: +371 67 323 666
UAB Sicor Biotech filiāle Latvijā Tel: +371 67 323 666
UAB “Sicor Biotech” filiāle Latvijā Telephone: +371 67 323 666
UAB “Sicor Biotech” filiāle Latvijā
UAB “Sicor Biotech” Tel: +370 5 266 02
UAB “Sicor Biotech” Tel: +370 5 266 02 03
UAB “Sicor Biotech” Tel: +370 5 266 02 03
Sicor Biotech filiāle Latvijā Tel: + 37167323666
UAB “Sicor Biotech” Tel: +370 5 266 02 03
Tel: +372 6610801
UAB “Sicor Biotech” Tel: +370 5 266 02 03
Teva Eesti esindus UAB Sicor Biotech Eesti filiaal
UAB “Sicor Biotech” Tel: +370 5 266 0203
UAB “Sicor Biotech”
UAB “Sicor Biotech” Telephone: +370 5 266 02 03
Teва Фармасютикълс България ЕООД Телефон: +359 2 489 95 82
UAB „AstraZeneca Lietuva“ Tel: +370 5 2660550
UAB AstraZeneca Lietuva Tel: +370 5 2660550
UAB „Johnson & Johnson” Tel: +370 5 278 68 88
UAB „Johnson & Johnson“ Tel: +370 5 278 68 88
UAB „Sicor Biotech“ Eesti filiaal
UAB „Sicor Biotech“ Eesti filiaal Tel: +372 661 0801
UAB ″Baxter Lithuania″
UAB ”Baxter Lithuania”
UAB,,AstraZeneca Lietuva“ Tel: +370 5 2660550
UAB ,,AstraZeneca Lietuva“ Tel: +370 5 2660550
ualmindelige (mere end 1, men færre end 10 dyr ud af 1.000 dyr)
uncommon (more than 1 but less than 10 animals in 1,000 animals)
UCB Innere Medizin GmbH & Co.
UCB Innere Medizin GmbH & Co. KG
UCB Pharma S.A., Allée de la Recherche 60, B-1070 Bruxelles, Белгия.
UCB Pharma S.A, Allée de la Recherche 60, B-1070 Bruxelles, Belgium.
UCB Pharma S.A., Allée de la Recherche 60, B-1070 Bruxelles, Белгия.
UCB Pharma S.A., Allée de la Recherche 60, B-1070 Bruxelles, Belgium.
UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l’Alleud, Белгия.
UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l’Alleud, Belgium
UCB Pharma SA, Allee de la Recherche 60, B-1070 Brussels, Белгия
UCB Pharma SA, Allée de la Recherche 60, B-1070 Brussels, Belgium.
UCB Pharma SA, Allee de la Recherche 60, B-1070 Brussels, Белгия.
UCB Pharma S.A. Allée de la Recherche 60, B-1070 Brussels, Belgium.
UCB Pharma SA, Allee de la Recherche 60, B-1070 Brussels, Белгия.
UCB Pharma SA, Allée de la Recherche 60, B-1070 Brussels, Belgium.
UCB Pharma SA, Allée de la Recherche 60, B-1070 Bruxelles, Белгия.
UCB Pharma SA, Allée de la Recherche 60, B-1070 Bruxelles, Belgium.
UCB Pharma SA, Chemin du Foriest, B-1420 Braine-l’Alleud, Белгия или
UCB Pharma SA, Chemin du Foriest, B-1420 Braine-l’Alleud, Belgium or
UCB лого
UCB logo.
Uchovávajte mimo dohľadu a dosahu detí.
Keep out of the sight and reach of children.
Uchovávajte v chladničke (2 C – 8 C).
Store in a refrigerator (2ºC - 8ºC).
Uchovávajte v chladničke pri teplote (2 ˚C – 8 ˚C).
Store in a refrigerator (2ºC - 8ºC).
Uchovávajte v chladničke.
Store in a refrigerator.
Uchovávejte do 30 °C (PVC/PVDC/hliníkové blistry) nebo Žádné zvláštní podmínky uchovávání (pro celohliníkové blistry)
Store below 30°C (for PVC/PVDC/aluminium blisters)
Uchovávejte při teplotě do 25°C.
Do not store above 25°C.
Uchovávejte při teplotě do 30 °C.
Do not store above 30°C.
Uchovávejte tyto nádobky v lahvičce.
Keep the canisters in the bottle.
Uchovávejte v dobře uzavřeném obalu, aby byl přípravek chráněn před vlhkostí.
Keep the container tightly closed in order to protect from moisture.
Uchovávejte v dobře uzavřeném obalu, aby byl přípravek chráněn před vlhkostí.
Keep the container tightly closed to protect from moisture.
Uchovávejte v dobře uzavřeném vnitřním obalu, aby byl chráněn před vlhkem.
Keep the container tightly closed in order to protect from moisture.
Uchovávejte v dobře uzavřeném vnitřním obalu, aby byl přípravek chráněn před vlhkem.
Keep the container tightly closed in order to protect from moisture.
Ud over de kliniske symptomer, der er nævnt i sektion 4.6, kan en ti gange overdosis medføre en byld i en af de submandibulære lymfeknuder.
In addition to the clinical signs given under section 4.6, vaccination with a ten times overdose may induce an abscess in one of the submandibular lymph nodes.
Udgangsstoffet metaboliseres af cytokrom P450-familierne 3A4 og 2E1 i leveren, og i mindre grad af 2C9.
The parent drug is metabolised by the hepatic cytochrome P450 families 3A4 and 2E1, and to a lesser extent by 2C9.
UDL.D. {måneder/år}
EXP {month/year}
Udløbsdato: { måned/år}
EXP { month/year}
Udløbsdato: {måned/år}
EXP { month/year}
UFH може да се прилага в дози, необходими за поддържане на проходимостта на централен венозен или артериален катетър (вж. точки 4.3)
UFH can be administered at doses necessary to maintain a patent central venous or arterial catheter (see section 4.3).
UFH може да се прилага в дози, необходими за поддържане на проходимостта на централен венозен или артериален катетър (вж. точки 4.3).
UFH can be administered at doses necessary to maintain a patent central venous or arterial catheter (see sections 4.3).
UFH/енокс + GP IIb/IIIa инхибитор (N= 2 842) %
UFH/enox + GP IIb/IIIa inhibitor (N= 2,842)
UFH/енокс1 + GP IIb/IIIa инхибитор (%)
UFH/Enox1 + GP IIb/IIIa inhibitor (%)
Uforligeligheder:
Incompatibilities:
Ugotovili niso nobenih razmerij med AST (SGOT), ALT (SGPT), ali celokupnim bilirubinom in farmakokinetiko pemetrekseda.
No relationships between AST (SGOT), ALT (SGPT), or total bilirubin and pemetrexed pharmacokinetics were identified.
Ugotovili so naslednje deleže odziva:
The following response rates were observed:
Ugotovili so, da je plazemski očistek topotekana po intravenskem infundiranju v odmerku 0,5 do 1,5 mg/m2 5 zaporednih dni pri času infuzije 30 minut visok, in sicer 62 l/h (SD 22), kar pomeni približno 2/3 pretoka krvi skozi jetra.
Following intravenous administration of topotecan at doses of 0.5 to 1.5 mg/m2 as a 30 minute infusion daily for five days, topotecan demonstrated a high plasma clearance of 62 l/h (SD 22), corresponding to approximately 2/3 of liver blood flow.
Ugotovili so, da je plazemski očistek topotekana po intravenskem infundiranju v odmerku 0,5 do 1,5 mg/m2 pet zaporednih dni pri času infuzije 30 minut visok, in sicer 62 l/h (SD 22), kar pomeni približno 2/3 pretoka krvi skozi jetra.
Following intravenous administration of topotecan at doses of 0.5 to 1.5 mg/m2 as a 30 minute infusion daily for five days, topotecan demonstrated a high plasma clearance of 62 l/h (SD 22), corresponding to approximately 2/3 of liver blood flow.
Ugotovljeni v obdobju trženja
Headachec Dizzinessc
Ugotovljeno je bilo tudi, da je zdravilo Pravafenix 40 mg/160 mg v primerjavi z monoterapijo s pravastatinom 40 mg in fenofibratom 160 mg dodatno koristno za uravnavanje glavnih parametrov lipidov.
The incremental benefit of Pravafenix 40 mg/160 mg on main lipid parameters versus Pravastatin 40 mg and Fenofibrate 160 mg monotherapy was also established.
UGT и CYP3A4 от атазанавир
UGT and CYP3A4 inhibition by
Ujedinjeno Kraljevstvo (Velika Britanija) Tel: + 44 (0) 1896 664000
Ujedinjeno Kraljevstvo (Velika Britanija) Tel: + 44 (0)1896 664000
Ujistěte se, že váš lékař ví, že:
Make sure your doctor knows:
UK-Suffolk IP30 9 UP
UK-Suffolk IP30 9 UP Tel: + 44 (0) 1359 243243
UK-Suffolk IP30 9 UP Tel: + 44 (0) 1359 243243
UK-Suffolk IP30 9 UP Tel: 44 (0) 1359 243243
Ukázalo sa, že trabektedín vyvíja antiproliferatívnu in vitro a in vivo činnosť proti celému radu línií ľudských nádorových buniek a experimentálnych nádorov, vrátane malignít ako je sarkóm, rakovina prsníka, nemalobunečný pľúcny karcinóm, rakovina vaječníkov a melanóm.
Trabectedin has been shown to exert antiproliferative in vitro and in vivo activity against a range of human tumour cell lines and experimental tumours, including malignancies such as sarcoma, breast, non-small cell lung, ovarian and melanoma.
ULN = Горна граница на нормата
ULN = Upper Limit of Normal.
ULN = горна граница на нормата за лечебното заведение
ULN = upper limit of normal for the institution
ULN = горна граница на нормата за лечебното заведение AST = аспартат-аминотрансфераза
ULN = upper limit of normal for the institution AST = aspartate aminotransferase
Ultibro Breezhaler 85 mcg/43 mcg прах за инхалации индакатерол/ гликопирониум
Ultibro Breezhaler 85 mcg/43 mcg inhalation powder Indacaterol/glycopyrronium
Ultibro Breezhaler 85 микрограма/43 микрограма прах за инхалации, твърди капсули
Ultibro Breezhaler 85 micrograms/43 micrograms inhalation powder, hard capsules
Ultibro Breezhaler 85 микрограма/43 микрограма прах за инхалации, твърди капсули индакатерол/ гликопирониум
Ultibro Breezhaler 85 micrograms/43 micrograms inhalation powder, hard capsules Indacaterol/glycopyrronium
Ultibro Breezhaler 85 микрограма/43 микрограма прах за инхалация, твърди капсули
Ultibro Breezhaler 85 micrograms/43 micrograms, inhalation powder hard capsules
Ultibro Breezhaler демонстрира статистически значимо по-изразено подобрение спрямо тиотропиум в процента на “дни, в които е възможно да се извършват обичайни ежедневни дейности” в продължение на 26-те седмици (8,45%, p<0,001).
Ultibro Breezhaler demonstrated a statistically superior improvement versus tiotropium in the percentage of “days able to perform usual daily activities” over 26 weeks (8.45%, p<0.001).
Ultibro Breezhaler е еднодозов инхалатор.
Ultibro Breezhaler is a single-dose inhaler.
Ultibro Breezhaler може да се използва при пациенти с леко до умерено бъбречно увреждане в препоръчителната доза.
Ultibro Breezhaler can be used at the recommended dose in patients with mild to moderate renal impairment.
Ultibro Breezhaler може да се прилага в препоръчителната доза при пациенти с лека до умерена степен на чернодробно увреждане.
Ultibro Breezhaler can be used at the recommended dose in patients with mild and moderate hepatic impairment.
Ultibro Breezhaler не е показан за лечение на остри епизоди на бронхоспазъм.
Ultibro Breezhaler is not indicated for the treatment of acute episodes of bronchospasm.
Ultibro Breezhaler не е проучван при пациенти с недобре контролиран захарен диабет.
Ultibro Breezhaler has not been investigated in patients for whom diabetes mellitus is not well controlled.
Ultibro Breezhaler повишава ФЕО1 стандартизирана площ под кривата AUC0-12, след прилагане на дозата (първична крайна точка) със 140 ml на 26-та седмица (p<0,001) при сравнение с флутиказон/салметерол.
Ultibro Breezhaler increased post-dose FEV1 AUC0-12 (primary endpoint) by 140 ml at 26 weeks (p<0.001) compared to fluticasone/salmeterol.
Ultibro Breezhaler трябва да се прилага с повишено внимание при пациенти със сърдечно- съдови нарушения (коронарна болест на сърцето, остър миокарден инфаркт, сърдечни аритмии, хипертония).
Ultibro Breezhaler should be used with caution in patients with cardiovascular disorders (coronary artery disease, acute myocardial infarction, cardiac arrhythmias, hypertension).
Ultibro Breezhaler – гликопирониум
Ultibro Breezhaler – glycopyrronium
Ultibro Breezhaler – индакатерол
Ultibro Breezhaler – indacaterol
Ultibro Breezhaler – плацебо
Ultibro Breezhaler – placebo
Ultibro Breezhaler – тиотропиум
Ultibro Breezhaler – tiotropium
Ulunar Breezhaler 85 mcg/43 mcg прах за инхалации индакатерол/ гликопирониум
Ulunar Breezhaler 85 mcg/43 mcg inhalation powder Indacaterol/glycopyrronium
Ulunar Breezhaler 85 микрограма/43 микрограма прах за инхалации, твърди капсули
Ulunar Breezhaler 85 micrograms/43 micrograms inhalation powder, hard capsules
Ulunar Breezhaler 85 микрограма/43 микрограма прах за инхалации, твърди капсули индакатерол/ гликопирониум
Ulunar Breezhaler 85 micrograms/43 micrograms inhalation powder, hard capsules Indacaterol/glycopyrronium
Ulunar Breezhaler 85 микрограма/43 микрограма прах за инхалация, твърди капсули
Ulunar Breezhaler 85 micrograms/43 micrograms, inhalation powder hard capsules
Ulunar Breezhaler демонстрира статистически значимо по-изразено подобрение спрямо тиотропиум в процента на “дни, в които е възможно да се извършват обичайни ежедневни дейности” в продължение на 26-те седмици (8,45%, p<0,001).
Ulunar Breezhaler demonstrated a statistically superior improvement versus tiotropium in the percentage of “days able to perform usual daily activities” over 26 weeks (8.45%, p<0.001).
Ulunar Breezhaler е еднодозов инхалатор.
Ulunar Breezhaler is a single-dose inhaler.
Ulunar Breezhaler може да се използва при пациенти с леко до умерено бъбречно увреждане в препоръчителната доза.
Ulunar Breezhaler can be used at the recommended dose in patients with mild to moderate renal impairment.
Ulunar Breezhaler може да се прилага в препоръчителната доза при пациенти с лека до умерена степен на чернодробно увреждане.
Ulunar Breezhaler can be used at the recommended dose in patients with mild and moderate hepatic impairment.
Ulunar Breezhaler не е показан за лечение на остри епизоди на бронхоспазъм.
Ulunar Breezhaler is not indicated for the treatment of acute episodes of bronchospasm.
Ulunar Breezhaler не е проучван при пациенти с недобре контролиран захарен диабет.
Ulunar Breezhaler has not been investigated in patients for whom diabetes mellitus is not well controlled.
Ulunar Breezhaler повишава ФЕО1 стандартизирана площ под кривата AUC0-12, след прилагане на дозата (първична крайна точка) със 140 ml на 26-та седмица (p<0,001) при сравнение с флутиказон/салметерол.
Ulunar Breezhaler increased post-dose FEV1 AUC0-12 (primary endpoint) by 140 ml at 26 weeks (p<0.001) compared to fluticasone/salmeterol.
Ulunar Breezhaler трябва да се прилага с повишено внимание при пациенти със сърдечно- съдови нарушения (коронарна болест на сърцето, остър миокарден инфаркт, сърдечни аритмии, хипертония).
Ulunar Breezhaler should be used with caution in patients with cardiovascular disorders (coronary artery disease, acute myocardial infarction, cardiac arrhythmias, hypertension).
Ulunar Breezhaler – гликопирониум
Ulunar Breezhaler – glycopyrronium
Ulunar Breezhaler – индакатерол
Ulunar Breezhaler – indacaterol
Ulunar Breezhaler – плацебо
Ulunar Breezhaler – placebo
Ulunar Breezhaler – тиотропиум
Ulunar Breezhaler – tiotropium
Umerjanje nadzornih naprav za NO, NO2 in O2
NO, NO2 and O2 monitor calibration
Umirjanje vnetja in lajšanje bolečine pri akutnih in kroničnih mišično-skeletnih obolenjih pri psih.
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.
Umirjanje vnetja in lajšanje bolečine pri akutnih in kroničnih mišično-skeletnih obolenjih.
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.
Uncinaria stenocephala (зрели възрастни)
Uncinaria stenocephala (mature adult)
Uncommon Болка, свързана с процедурата  интервенции
Uncommon Procedural pain
Under anestesi bör monitorering och vätsketerapi övervägas som standardrutin.
During anaesthesia, monitoring and fluid therapy should be considered as standard practice.
Under en 4 timmar lång hemodialysperiod avlägsnades 55 % av avibaktamdosen.
During a 4-hour haemodialysis period, 55% of the avibactam dose was removed.
Under hiv-behandling kan viktökning och ökade nivåer av lipider och glukos i blodet förekomma.
During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose.
Under sådana omständigheter bör utsättande av ceftarolinfosamil och stödåtgärder tillsammans med administrering av specifik behandling mot Clostridium difficile övervägas.
In such circumstance, the discontinuation of therapy with ceftaroline fosamil and the use of supportive measures together with the administration of specific treatment for Clostridium difficile should be considered.
Undvik användande på dehydrerade, hypovolemiska eller hypotensiva djur eftersom det finns en möjlig risk för njurskada.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.
Undvik användande på dehydrerade, hypovolemiska eller hypotensiva djur eftersom det finns en möjlig risk för njurtoxicitet.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.
Undvik användande på dehydrerade, hypovolemiska eller hypotensiva djur eftersom det finns en möjlig risk för njurtoxicitet.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.
Undvik användande på djur som är uttorkade, lider av blodförlust eller lågt blodtryck eftersom det finns en möjlig risk för njurskada.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.
Undvik användande på djur som är uttorkade, lider av blodförlust eller lågt blodtryck eftersom det finns en möjlig risk för njurskada.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.
Undvik användning till dehydrerade, hypovolemiska eller hypotensiva djur eftersom det finns en möjlig risk för njurtoxicitet.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.
Undvik användning till djur som är uttorkade, lider av blodförlust eller lågt blodtryck eftersom det finns en möjlig risk för njurskada.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.
Undvik att använda till djur som är uttorkade, lider av blodförlust eller lågt blodtryck eftersom det finns en möjlig risk för njurskada.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.
Undvik att förorena flaskan under användande.
Avoid introduction of contamination during use.
Undvik att förorena flaskan under användningen.
Avoid introduction of contamination during use.
Undvik kontamination under användande.
Avoid introduction of contamination during use.
unetus (unehäired), ärevus, segasus
feeling lethargic (somnolence); trembling; dizziness; disturbed taste
Ungefär 50 % av den administrerade dosen elimineras via urin och resterande via faeces.
Approximately 50 % of the administered dose is eliminated via urine and the remainder via faeces.
Ungefär 75 % av den administrerade dosen elimineras via faeces och resterande via urin.
Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.
Ungefär 75 % av den administrerade dosen elimineras via faeces och resterande via urin.
Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.
Ungefär 87 % av patienterna hade ≤10 APACHE II-poäng och 4,0 % hade bakteriemi vid baslinjen.
Approximately 87% of patients had APACHE II scores of ≤ 10 and 4.0% had bacteraemia at baseline.
Ungefärlig koncentration av ceftarolin (mg/ml)
Approximate ceftaroline concentration (mg/ml)
Ungefärlig koncentration av ceftazidim/avibaktam (mg/ml)
Approximate ceftazidime/avibactam concentration (mg/mL)
UNIK IDENTITETSBETECKNING – I ETT FORMAT LÄSBART FÖR MÄNSKLIGT ÖGA
UNIQUE IDENTIFIER - HUMAN READABLE DATA
UNIK IDENTITETSBETECKNING – I ETT FORMAT LÄSBART FÖR MÄNSKLIGT ÖGA
UNIQUE IDENTIFIER – HUMAN READABLE DATA
UNIK IDENTITETSBETECKNING – TVÅDIMENSIONELL STRECKKOD
UNIQUE IDENTIFIER – 2D BARCODE
Unit 12 Distribution Centre, Shannon Industrial Estate, Shannon, Co.
Unit 12 Distribution Centre, Shannon Industrial Estate, Shannon, Co. Clare Ireland
Unit 12, The Distribution Centre, Shannon Industrial Estate, Shannon, Co.
Unit 12, The Distribution Centre, Shannon Industrial Estate, Shannon, Co. Clare,
Unit 19, QuadrumPark, Old Portsmouth Road Peasmarsh, Guildford, Surrey, GU3 1LU Обединено кралство
Unit 19, Quadrum Park, Old Portsmouth Road Peasmarsh, Guildford, Surrey, GU3 1LU United Kingdom
Unit 19, QuadrumPark, Old Portsmouth Road, Peasmarsh, Guildford, Surrey, GU3 1LU Обединено кралство
Unit 19, Quadrum Park, Old Portsmouth Road, Peasmarsh, Guildford, Surrey, GU3 1LU United Kingdom
Unit 2, Valwall RoadValwall Business Park Maidenhead
Unit 2, Vanwall Road Vanwall Business Park Maidenhead
Unit 2, Vanwall RoadVanwall Business Park Maidenhead
Unit 2, Vanwall Road Vanwall Business Park Maidenhead
Unit 22, Quest Park Wheatley Hall Road Doncaster, DN2 4LT Обединено кралство
Unit 22, Quest Park Wheatley Hall Road Doncaster, DN2 4LT United Kingdom
Unit 35 Baldoyle Industrial Estate, Grange Road, Dublin 13, Ирландия.
Unit 35 Baldoyle Industrial Estate, Grange Road, Dublin 13, Ireland.
Unit 6, Fulcrum 1, Solent Way, Solent Business Park, Whiteley, Fareham, Hampshire, PO15 7FE, Обединено кралство
Unit 6, Fulcrum 1, Solent Way, Solent Business Park, Whiteley, Fareham, Hampshire, PO15 7FE United Kingdom
United Kingdom
Latvija
United Kingdom
Latvija United Kingdom
United Kingdom
UNITED KINGDOM.
United Kingdom (Обединеното Кралство)
UNITED KINGDOM
United Kingdom Consilient Health (UK) Ltd.
Consilient Health (UK) Ltd.
United Kingdom GlaxoSmithKline UK Ltd Tel: + 44 (0)800 221441 customercontactuk@gsk.com
United Kingdom GlaxoSmithKline UK Ltd Tel: + 44 (0)800 221441
United Kingdom GlaxoSmithKline UK Tel: + 44 (0) 800 221 441 customercontactuk@gsk.com
United Kingdom GlaxoSmithKline UK Tel: + 44 (0)800 221 441 customercontactuk@gsk.com
United Kingdom GlaxoSmithKline UK Tel: + 44 (0)808 100 9997 customercontactuk@gsk.com
Tel: + 44 (0)808 100 9997 customercontactuk@gsk.com
United Kingdom GlaxoSmithKline UK Tel: + 44 (0)808 100 9997 lv-epasts@gsk.com customercontactuk@gsk.com
United Kingdom GlaxoSmithKline UK Tel: + 44 (0)808 100 9997 customercontactuk@gsk.com
United Kingdom LEO Laboratories Ltd Tel: +44 1844 347333
LEO Laboratories Ltd Tel: +44 (0) 1844 347333
United Kingdom Teva UK Limited Tel: +44 1977628500
United Kingdom Teva UK Limited Tel: +44 1977 628500
Units 1, 2, 3, 5, 6, 7 & 8 Euro Way Blagrove
Units 1, 2, 3, 5, 6, 7 & 8 Euro Way Industrial Estate Blagrove
Units 2-7, Wye Valley Business Park
Units 2-7, Wye Valley Business Park Brecon Road, Hay-on-Wye, Hereford HR3 5PG
Unituxin има много нежелани реакции, което ще се отрази върху способността за шофиране и работа с машини
Unituxin has many side effects, and this will affect your ability to drive and use machines.
Unituxin разпознава и се прикрепва към „мишена“от клетъчната повърхност, наречена „GD2“ (дисиалоганглиозид).
Unituxin recognises and attaches to a cell surface target called ‘GD2’.
Unituxin се използва за лечение на деца с „високорисков“ невробластом, форма на рака с висок риск от повторна поява.
Unituxin is used to treat children with ‘high-risk’ neuroblastoma, the form of the cancer that has a high chance of returning.
Unituxin се използва за лечение на „високорисков невробластом“ при бебета, деца и юноши на възраст от 12 месеца до 17 години.
Unituxin is used to treat ‘high-risk neuroblastoma’ in babies, children and adolescents aged 12 months to 17 years old.
Unituxin се използва с три други лекарства:
Unituxin is used with three other medicines:
Unituxin се прилага чрез венозна инфузия – за около 10 часа дневно в продължение на четири дни.
Unituxin is given as a drip into one of your veins – for about 10 hours each day for four days.
Uničenje tumorskih celic prav tako nastopi s pomočjo ishemične nekroze, ki nastane kot posledica žilne okluzije, za katero se zdi, da jo delno povzroči sproščanje tromboksana A2.
Tumour cell death also occurs through ischaemic necrosis secondary to vascular occlusion that appears to be partly mediated by thromboxane A2 release.
UpCard 0,75 mg tabletter til hunde UpCard 3 mg tabletter til hunde UpCard 7,5 mg tabletter til hunde UpCard 18 mg tabletter til hunde
UpCard 0.75 mg tablets for dogs UpCard 3 mg tablets for dogs UpCard 7.5 mg tablets for dogs UpCard 18 mg tablets for dogs
UpCard 0,75 mg tabletter til hunde UpCard 3 mg tabletter til hunde UpCard 7,5 mg tabletter til hunde UpCard 18 mg tabletter til hunde torasemid
UpCard 0.75 mg tablets for dogs UpCard 3 mg tablets for dogs UpCard 7.5 mg tablets for dogs UpCard 18 mg tablets for dogs torasemide
UpCard 3 mg, 7,5 mg og 18 mg tabletter: aflange hvide til off-white tabletter med 3 delekærve på hver side.
UpCard 3 mg, 7.5 mg and 18 mg tablets are oblong white to off-white tablets with 3 break-lines on each side.
UpCard 3 mg, 7,5 mg og 18 mg tabletter: aflange hvide til off-white tabletter med 3 delekærve på hver side.
UpCard 3 mg, 7.5 mg and 18 mg tablets: oblong white to off-white tablets with 3 break-lines on each side.
UpCard 7,5 mg 7,5 mg torasemid
UpCard 7.5 mg 7.5 mg of torasemide
UpCard tabletter fås i blisterpakninger med 10 tabletter pr. blisterpakning.
UpCard tablets are supplied in blister packs with 10 tablets per blister pack.